abstract |
In one non-limiting embodiment, the present disclosure provides a freeze-dried formulation containing an IL-31 antagonist (eg, an anti-IL-31RA antibody) as an active ingredient, arginine and/or a salt thereof, and sucrose and/or Or to a lyophilized formulation comprising trehalose. In another non-limiting embodiment, the present disclosure relates to a solution formulation containing an IL-31 antagonist as an active ingredient, the solution formulation comprising arginine and/or a salt thereof. In one non-limiting embodiment, the present disclosure provides a method of stabilizing an antibody (eg, an anti-IL-31RA antibody) in an antibody containing formulation, a method of inhibiting the association (association formation) of the antibody, and a charge A method for reducing red heterocomponents, it relates to a method comprising arginine and/or a salt thereof, and/or sucrose and/or trehalose in a formulation. |